Pregnancy outcomes after first trimester exposure to @entity21938 / XXXX .

@entity4899 @entity1 @entity154 @entity353 @entity6 @entity21938 @entity600 @entity299 @entity4696 @entity393
BACKGROUND: @entity4899 was withdrawn from the U.S. market in 1997 because of its association with @entity299 in adults. The combination of @entity4899 and @entity21938 had been widely used to promote @entity353 , and many @entity1 were inadvertently exposed during the first trimester of pregnancy. The possible effect on the developing fetus has not been studied. METHODS: Controlled prospective cohort study comparing 98 @entity1 who had taken @entity21938 / @entity4899 to 233 @entity1 who had not, all of whom contacted the California Teratogen Information Service during pregnancy. RESULTS: The proportion of liveborn @entity1 with @entity4696 was similar in the two groups (3.6% vs. 1.0%, relative risk (RR) 3.59; 95% confidence interval (CI) 0.61, 21.10), as was the proportion of @entity1 with >or=3 @entity154 (11.7% vs. 7.6%, RR 1.53; 95% CI 0.61, 3.82). Furthermore, no pattern of @entity600 was identified. There were no significant differences between the groups in spontaneous @entity393 (6.1% vs. 8.2%, P = 0.65) or premature delivery (8.6% vs. 7.7%, P = 0.95). Birth weight and head circumference were significantly increased in the exposed group; however, these differences were not associated with anorexiant use itself. The rate of gestational @entity6 was significantly increased in pregnant @entity1 who took @entity21938 / @entity4899 during the first trimester of pregnancy. CONCLUSIONS: Although it is not possible from this study to rule out weak to moderate associations, the lack of an increased risk of spontaneous @entity393 , and major or @entity154 in the offspring of @entity1 who took @entity21938 / @entity4899 at the recommended daily dose during the first trimester of pregnancy is reassuring.
